NCT06559059 Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs
| NCT ID | NCT06559059 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Lung Cancer Diagnosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,800 participants |
| Start Date | 2024-06-18 |
| Primary Completion | 2027-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,800 participants in total. It began in 2024-06-18 with a primary completion date of 2027-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the pragmatic trial to test the effectiveness of an existing, ongoing clinical service, the VA National TeleOncology program (NTO), a multilevel telehealth population health management program. The primary aims are to study the intervention and determine its effectiveness on telehealth engagement, clinical quality, and healthcare cost outcomes across personal characteristics.
Eligibility Criteria
Patients Inclusion Criteria: 1. A Veteran 2. Aged 18 years or older 3. Newly diagnosed with lung, prostate, breast, or colon cancer within 3 months of telemedicine visit 4. Engaged in an oncology visit during the 36-month analysis period at a Veterans Affairs Medical Center (VAMC) location. VAMC Providers and Staff Inclusion Criteria: 1. Provider or staff member at one of the VAMC locations including physicians, nurse practitioners, physicians' assistants, and nurses caring for Veterans 2. Providers or staff members having helped provide care for at least 5 Veterans with cancer in the previous 6 months at a VAMC location Patients Exclusion Criteria: 1. Veterans who have not seen any providers in the VA within the past year 2. Patients previously diagnosed with lung, prostate, breast, or colon cancer 3. Pregnant patients VAMC Providers and Staff Exclusion Criteria: 1\. Providers or staff members who do not help treat Veterans with specified cancers in oncology at the VA
Contact & Investigator
Danil Makarov, MD, MHS
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT06559059 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer Diagnosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06559059 currently recruiting?
Yes, NCT06559059 is actively recruiting participants. Contact the research team at Janeth.juarezpadilla@nyulangone.org for enrollment information.
Where is the NCT06559059 trial being conducted?
This trial is being conducted at Brooklyn, United States, Jamaica, United States, New York, United States, New York, United States and 1 additional location.
Who is sponsoring the NCT06559059 clinical trial?
NCT06559059 is sponsored by NYU Langone Health. The principal investigator is Danil Makarov, MD, MHS at NYU Langone Health. The trial plans to enroll 1,800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.